Data-driven policymaking depends on transparency. 📊 Massachusetts continues to benefit from robust hospital financial reporting that allows employers, consumers, policymakers, and other stakeholders to better understand the financial condition of the health care system. 🤝

💡 Massachusetts needs a comprehensive approach to health care affordability that addresses prices, financial performance and solvency. Stronger hospital oversight, enhanced financial data collection, expanded cost-growth accountability and greater pharmaceutical transparency is needed to address the underlying drivers of spending across the entire system.

🏥 Hospital financial reporting is important, but reporting alone does not ensure accountability. A stronger framework is needed to monitor hospital and health system solvency, including minimum financial standards and corrective action plans when organizations face financial challenges. System stability requires meaningful oversight.

#DYK? Unlike health plans, hospitals are not subject to strict oversight, transparency & accountability. Hospitals in Massachusetts have greater flexibility to operate, and unlike health plans, are not subject to caps on profit margins or mandates regarding expenditure allocation. Learn more: mahp.com/wp-content/uploads/…

💊 Prescription drug costs remain a major driver of health care spending. Addressing affordability requires stronger oversight, transparency, and accountability across the pharmaceutical supply chain to protect consumers & employers.

Hospital financial performance has shown signs of greater stability as pandemic-related challenges have eased. 📈 Declining temporary staffing costs and moderating inflation have contributed to improved financial performance across many Massachusetts hospitals over the past two years. 👩‍⚕️ Learn more from @Mass_CHIA here: chiamass.gov/insights-analys…

💊 Drug costs continue to rise, with median launch prices increasing more than sixfold—from $38,857 in 2008–2013 to $254,213 in 2020–2025. Yet pharmaceutical manufacturers are not held to the same accountability for the prices they set, while employers & consumers face the consequences. jamanetwork.com/journals/jam…

Understanding hospital finances helps inform a broader affordability discussion. 💡 Provider prices and other health care costs ultimately affect employers, families, and taxpayers through the cost of health coverage. 📈 Learn more from @Mass_CHIA here: chiamass.gov/insights-analys…

#DYK?💊The median annual list price for a new prescription drug approved in the U.S. was $216,000 in 2025, well above the $180,000 median in 2021, according to a @Reuters analysis. Yet drug manufacturers face no comparable accountability to affordability as health plans do. Learn more here: reuters.com/business/healthc…

Strong policy starts with strong data. 📚 Massachusetts has built one of the nation's most comprehensive systems for tracking hospital finances, allowing policymakers to evaluate trends in revenues, expenses, margins, liquidity, and solvency—not just individual headlines. 📊 Learn more from @Mass_CHIA: chiamass.gov/insights-analys…

⚖️ Accountability should extend across the entire health care system. Health plans face extensive oversight of premiums, spending and financial performance, yet key drivers of health care costs—including providers & pharmaceutical manufacturers—face different levels of accountability. Affordability requires a system-wide approach. Learn more here: mahp.com/wp-content/uploads/…

💡 Quick Fact: Commercial health care prices are negotiated between health plans and providers, and those negotiated prices ultimately influence the cost of health coverage. Greater transparency into provider price variation helps inform discussions about long-term affordability. 📈

📈 Data Drop: Academic Medical Centers had the highest median statewide relative price (S-RP) in 2024 at 1.10, meaning prices were about 10% above the statewide average. Teaching hospitals had a median S-RP of 0.96, while community and community-HPP hospitals had median S-RPs below the statewide average. Learn more from @Mass_CHIA here: chiamass.gov/insights-analys…

📊 From 2017–2024, pharmaceutical manufacturers' average annual net income margin was 23.2%. Their lowest annual margin during that period was 20.0%, still higher than the highest annual margin reported by any other sector in the analysis. Profitability is an important part of the drug affordability conversation. Learn more here: csrxp.org/out-of-control-dru…

Hospital revenue trends provide important context for understanding financial performance. 📈 In the latest @Mass_CHIA data, other operating revenue totaled approximately $5.7 billion through March 31, 2026. Looking across all revenue sources provides a more complete understanding of hospital financial performance. 💡 Learn more here: chiamass.gov/insights-analys…

MAHP is honored to bring together leaders from across health care snd government for a timely conversation on AI policy, governance, oversight & responsible innovation. A big thank you to our panelists: Susan Adams, SVP of @MassLeague; Senator Cynthia Stone Creem; Josh Orr, VP, Privacy & Spdcial Investigations Unit, General Counsel of Point32Health; and Zhao Zhang, Deluty Medicaid Director at @MassHHS.

🤖 We’re diving into real-world examples of how AI is being put into practice across the health care system, from digital transformation to clinical applications. Lee Leiber and Adrian H. Zai of @UMassChan are sharing insights on what implementation looks like in practice, and what it takes to use AI effectively & responsibly. 🏥

Up now: @CHAI_nonprofit provides a national perspective on building trust in health care AI, discussing how to advance responsible AI development, deployment and government through standards, tools & best practices. 💻🏥

🤖 MAHP and @ForHealthCnsltg are pleased to host today’s Policy Forum, AI in Health Care: Innovation, Governance, and the Future of AI, for a timely conversation on the opportunities, challenges & future of AI in health care. A special thank you to our Forum Sponsor, @CodoxoInc , for helping make today’s conversation possible!

⚖️ Who is accountable for rising health care costs? Health plans face premium rate review, financial reporting, medical loss ratio requirements and capital standards. Pharmaceutical manufacturers can set drug prices without a comparable limit on profit margins. Affordability requires accountability across the entire health care system. Learn more here: mahp.com/wp-content/uploads/…